Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma

Ali Rihani; Tom van Maerken; Bram de Wilde; Fjoralba Zeka; Geneviève Laureys; Koen Norga; Gian Paolo Tonini; Simona Coco; Rogier Versteeg; Rosa Noguera; Johannes H. Schulte; Angelika Eggert; Raymond L. Stallings; Frank Speleman; Jo Vandesompele

doi:https://doi.org/10.1002/pbc.24927

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma

Ali Rihani, Tom van Maerken, Bram de Wilde, Fjoralba Zeka, Geneviève Laureys, Koen Norga, Gian Paolo Tonini, Simona Coco, Rogier Versteeg, Rosa Noguera, Johannes H. Schulte, Angelika Eggert, Raymond L. Stallings, Frank Speleman, Jo Vandesompele

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor entities, a protective effect has also been reported in certain other cancers. In this study, we evaluated the association of MDM2 SNP309 with outcome in 496 patients with neuroblastoma and its effect on MDM2 expression. No significant difference in overall or event-free survival was observed among patients with neuroblastoma with or without MDM2 SNP309. The presence of SNP309 does not affect MDM2 expression in neuroblastoma

Original language	English
Pages (from-to)	1867-1870
Journal	Pediatric blood & cancer
Volume	61
Issue number	10
DOIs	https://doi.org/10.1002/pbc.24927
Publication status	Published - 2014

Access to Document

https://doi.org/10.1002/pbc.24927

Cite this

Rihani, A., van Maerken, T., de Wilde, B., Zeka, F., Laureys, G., Norga, K., Tonini, G. P., Coco, S., Versteeg, R., Noguera, R., Schulte, J. H., Eggert, A., Stallings, R. L., Speleman, F., & Vandesompele, J. (2014). Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatric blood & cancer, 61(10), 1867-1870. https://doi.org/10.1002/pbc.24927

@article{80bd93d536994634aaf5ab1e1b50efbe,

title = "Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma",

abstract = "While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor entities, a protective effect has also been reported in certain other cancers. In this study, we evaluated the association of MDM2 SNP309 with outcome in 496 patients with neuroblastoma and its effect on MDM2 expression. No significant difference in overall or event-free survival was observed among patients with neuroblastoma with or without MDM2 SNP309. The presence of SNP309 does not affect MDM2 expression in neuroblastoma",

author = "Ali Rihani and {van Maerken}, Tom and {de Wilde}, Bram and Fjoralba Zeka and Genevi{\`e}ve Laureys and Koen Norga and Tonini, {Gian Paolo} and Simona Coco and Rogier Versteeg and Rosa Noguera and Schulte, {Johannes H.} and Angelika Eggert and Stallings, {Raymond L.} and Frank Speleman and Jo Vandesompele",

year = "2014",

doi = "https://doi.org/10.1002/pbc.24927",

language = "English",

volume = "61",

pages = "1867--1870",

journal = "Pediatric blood & cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Rihani, A, van Maerken, T, de Wilde, B, Zeka, F, Laureys, G, Norga, K, Tonini, GP, Coco, S, Versteeg, R, Noguera, R, Schulte, JH, Eggert, A, Stallings, RL, Speleman, F & Vandesompele, J 2014, 'Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma', Pediatric blood & cancer, vol. 61, no. 10, pp. 1867-1870. https://doi.org/10.1002/pbc.24927

TY - JOUR

T1 - Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma

AU - Rihani, Ali

AU - van Maerken, Tom

AU - de Wilde, Bram

AU - Zeka, Fjoralba

AU - Laureys, Geneviève

AU - Norga, Koen

AU - Tonini, Gian Paolo

AU - Coco, Simona

AU - Versteeg, Rogier

AU - Noguera, Rosa

AU - Schulte, Johannes H.

AU - Eggert, Angelika

AU - Stallings, Raymond L.

AU - Speleman, Frank

AU - Vandesompele, Jo

PY - 2014

Y1 - 2014

N2 - While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor entities, a protective effect has also been reported in certain other cancers. In this study, we evaluated the association of MDM2 SNP309 with outcome in 496 patients with neuroblastoma and its effect on MDM2 expression. No significant difference in overall or event-free survival was observed among patients with neuroblastoma with or without MDM2 SNP309. The presence of SNP309 does not affect MDM2 expression in neuroblastoma

AB - While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor entities, a protective effect has also been reported in certain other cancers. In this study, we evaluated the association of MDM2 SNP309 with outcome in 496 patients with neuroblastoma and its effect on MDM2 expression. No significant difference in overall or event-free survival was observed among patients with neuroblastoma with or without MDM2 SNP309. The presence of SNP309 does not affect MDM2 expression in neuroblastoma

U2 - https://doi.org/10.1002/pbc.24927

DO - https://doi.org/10.1002/pbc.24927

M3 - Article

C2 - 24391119

SN - 1545-5009

VL - 61

SP - 1867

EP - 1870

JO - Pediatric blood & cancer

JF - Pediatric blood & cancer

IS - 10

ER -